Genes
Scientists have discovered a novel adeno-associated virus (AAV) vector that can efficiently transduce airway cells, offering a potential solution for the treatment of cystic fibrosis. According to a recent study published in the American Journal of Respiratory Cell and Molecular Biology, researchers have developed a gene therapy, 4D-710, which utilizes
Cystic fibrosis
A new study published in Diabetologia by researchers from Newcastle University has revealed a detailed timeline of how cystic fibrosis (CF) damages the pancreas, leading to pancreatic exocrine insufficiency (PEI) and diabetes. The research used novel semi-quantitative scoring and artificial-intelligence-driven quantitative image analysis to examine pancreatic tissue samples from 29
Cystic fibrosis
Recent research at Careggi University Hospital in Florence, Italy, has made significant strides in understanding the treatment of cystic fibrosis-related chronic rhinosinusitis (CF-CRS). Historically, CF-CRS was managed with intranasal corticosteroids and endoscopic sinus surgery. However, the introduction of triple highly effective modulator therapy, elexacaftor-tezacaftor-ivacaftor (ETI), has shown promising results in
Cystic fibrosis
Research at the University of Sydney has presented fresh insights into the characteristics, treatment, and lung function outcomes of pulmonary exacerbations in people with cystic fibrosis. The study, published in the European Respiratory Journal, reveals that the management of exacerbations remains a significant clinical burden, even in the context of
Cystic fibrosis
Researchers at Duke University have made a significant breakthrough in the treatment of cystic fibrosis (CF) by investigating the effects of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on the sinonasal airspace of individuals with CF. The study found that ETI therapy led to significant increases in sinonasal airspace surface area and volume,
Cystic fibrosis
Researchers at the Medical University of Vienna have made a breakthrough in the early detection of cystic fibrosis (CF) by using arterialized oxygen tension (pO2) as a monitoring tool. The study published in Frontiers in Pediatrics reveals that early abnormal pO2 levels in young people with CF can significantly correlate
Cystic fibrosis
Research at Agia Sofia Children's Hospital in Athens, Greece, has found that the triple therapy of elexacaftor, tezacaftor, and ivacaftor (ETI) significantly improves sinonasal disease in young patients with cystic fibrosis. The study, which involved 15 patients, ages 14 to 20, found a statistically significant improvement in nasal
Children
Research conducted by Jouf University on cystic fibrosis has identified effective treatment modalities, including triple therapy and physiotherapy exercises, to reduce complications in children with the disease. The study also highlights the variable outcomes of nutritional interventions and emphasizes the need for reassessment. A comprehensive meta-analysis of existing research was
Ain Shams University
Research conducted by investigators from Ain Shams University in Cairo, Egypt, has highlighted the significant challenges in diagnosing and managing cystic fibrosis (CF) in Egyptian children. The study, which involved 31 children with CF, found that symptoms started as early as 3 months of age, with a median age of
Cystic fibrosis
The United States cystic fibrosis therapeutics market is poised for significant growth, driven by innovation in gene therapy, expanded patient access to CFTR modulators, enhanced awareness, and robust research efforts. The market is expected to reach $2.32 billion in 2024 and further reach $4.72 billion by the end
Cystic fibrosis
The United States cystic fibrosis therapeutics market is poised for significant growth, driven by innovation in gene therapy, expanded patient access to CFTR modulators, enhanced awareness, and robust research efforts. The market is expected to reach $2.32 billion in 2024 and further reach $4.72 billion by the end
Cystic fibrosis
The report, titled "Cystic Fibrosis - Global Clinical Trials Review," provides a comprehensive analysis of the clinical trials landscape for Cystic Fibrosis, offering key insights into the trial numbers and average enrollment across major countries worldwide. The report aggregates information from over 80 global clinical trial registries, journals,
